Code
3S011316
Duration
01 January 2016 → 31 December 2019
Funding
Research Foundation - Flanders (FWO)
Promotor
Fellow
Research disciplines
-
Medical and health sciences
- Immunology
- Morphological sciences
- Oncology
- Immunology
- Morphological sciences
- Oncology
- Biomarker discovery and evaluation
- Drug discovery and development
- Medicinal products
- Pharmaceutics
- Pharmacognosy and phytochemistry
- Pharmacology
- Pharmacotherapy
- Toxicology and toxinology
- Other pharmaceutical sciences
- Immunology
- Morphological sciences
- Oncology
Keywords
immunotherapy
cancer
mRNA therapeutics
Project description
Our recently developed mRNA replicon platform will be used to develop a novel immunotherapeutic combinatorial treatment for triple-negative breast cancer. The treatment consists of three parts: (1) an mRNA replicon based therapeutic cancer vaccine coding for the universal tumor-associated antigen p62, (2) an mRNA replicon that produces IL-12 under the control of a registered drug, and (3) an anti-PD-L1 immune checkpoint inhibitor